Heghine Khachatryan: New Evidence in Perioperative Hemostasis – Clinical Value of Perioperative TXA Use in General Surgery
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post by JAMA Surgery on LinkedIn:
“New Evidence in Perioperative Hemostasis
A newly published systematic review and meta-analysis in JAMA Surgery highlights the clinical value of perioperative tranexamic acid (TXA) use in general surgery.
Key findings:
- Significant reduction in intraoperative blood loss
- Decreased transfusion requirements
- Lower incidence of major bleeding
- No observed increase in thromboembolic events
These data further support TXA as an effective and safe component of modern blood management strategies when used appropriately and with proper patient selection.
For hematologists, surgeons, anesthesiologists, and perioperative teams, this reinforces the importance of evidence-based antifibrinolytic use as part of multidisciplinary bleeding control and patient blood management (PBM) programs.
Perioperative Use of Tranexamic Acid in General Surgery: A Systematic Review and Meta-Analysis
Published online: December 17, 2025 | JAMA Surgery
A meaningful step toward safer surgery, fewer transfusions, and better outcomes.”
Quoting JAMA Surgery’s post:
“Systematic review and meta-analysis: Prophylactic TXA use was associated with lower intraoperative blood loss, transfusion requirements, and major bleeding without an observed increase in thromboembolic or mortality risk.”
Title: Perioperative Use of Tranexamic Acid in General Surgery: A Systematic Review and Meta-Analysis
Authors: Lucas Monteiro Delgado, Bernardo Fontel Pompeu, Gabriel Henrique Acedo Martins, Mariana Lima Azevedo, Eric Pasqualotto, Thiago Celestino Chulam, Sérgio Mazzola Poli de Figueiredo
Read the full article here.
Stay updated and find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Feb 25, 2026, 16:47Alan Nurden: Platelet Defects Explain Bleeding in EHDS Patients
-
Feb 25, 2026, 16:40Mohammed Almohammadi: Uniting Leaders in Laboratory Hematology at the 1st Saudi ISLH Joint Conference
-
Feb 25, 2026, 16:37Salihu Asimawu: Inflammation Is Not a Disease – Hats Off to the Heroes Inside Us
-
Feb 25, 2026, 16:34Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
-
Feb 25, 2026, 16:25Tagreed Alkaltham: The Blood Banker Personality
-
Feb 25, 2026, 16:17Sanjay Ahuja: Insightful Talk on 100 Years of VWD by Jorge Di Paola
-
Feb 25, 2026, 15:20Michael Shapiro։ Creating Real Pathways for Trainees in Preventive Cardiology
-
Feb 25, 2026, 15:15Ajay Kumar: Plasma Component Quality Control Standards
-
Feb 25, 2026, 15:09Wolfgang Miesbach: Efficacy, Safety and Thrombosis Signals in Haemophilia A/B with Inhibitors